Review anchor
5-hydroxytryptamine receptor 1A
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-13
Evidence Snapshot
5-hydroxytryptamine receptor 1A
CHEMBL273
SINGLE PROTEIN
Rattus norvegicus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats 5-hydroxytryptamine receptor 1A as ChEMBL target CHEMBL273, mapped to UniProt P19327. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL273
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P19327
5-hydroxytryptamine receptor 1A
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why 5-hydroxytryptamine receptor 1A matters
5-hydroxytryptamine receptor 1A is reviewed as 5-hydroxytryptamine receptor 1A (UniProt P19327); the current evidence base includes 125 approved drugs, 6024 compounds, and 658 assays, with lead potency reaching pChEMBL 11.0.
Protein context
5-hydroxytryptamine receptor 1A
5-hydroxytryptamine receptor 1A Sequence length is 422 aa.
Review this target as 5-hydroxytryptamine receptor 1A, mapped to UniProt P19327. Sequence length is 422 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P19327
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 125 approved drugs, 6024 compounds, and 658 assays for this target. The dominant activity type is KI. CHEMBL3884161 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL3884161 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
125 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why 5-hydroxytryptamine receptor 1A matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P19327, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
6024
Total Compounds
658
Total Assays
125
Approved Drugs
IC50: 2035.0, KI: 5628.0, EC50: 26.0, KD: 13.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3884161
|
11.0 | Ki | — |
|
|
No preferred name
CHEMBL186423
|
11.0 | IC50 | — |
|
|
No preferred name
CHEMBL3764390
|
10.9 | Ki | — |
|
|
No preferred name
CHEMBL2387253
|
10.9 | Ki | — |
|
|
No preferred name
CHEMBL2112779
|
10.7 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
GEPIRONE
CHEMBL284092
|
2023 |
|
|
FLIBANSERIN
CHEMBL231068
|
2015 |
|
|
BREXPIPRAZOLE
CHEMBL2105760
|
2015 |
|
|
VILAZODONE
CHEMBL439849
|
2011 |
|
|
LURASIDONE
CHEMBL1237021
|
2010 |
|
|
ARIPIPRAZOLE
CHEMBL1112
|
2002 |
|
|
APOMORPHINE
CHEMBL53
|
2001 |
|
|
QUETIAPINE
CHEMBL716
|
1997 |
|
|
OLANZAPINE
CHEMBL715
|
1996 |
|
|
CARVEDILOL
CHEMBL723
|
1995 |
|
|
NEFAZODONE
CHEMBL623
|
1994 |
|
|
RISPERIDONE
CHEMBL85
|
1993 |
|
|
SUMATRIPTAN
CHEMBL128
|
1992 |
|
|
MOXONIDINE
CHEMBL19236
|
1991 |
|
|
DILEVALOL
CHEMBL27193
|
1990 |
|
|
CLOZAPINE
CHEMBL42
|
1989 |
|
|
PROPAFENONE
CHEMBL631
|
1989 |
|
|
ASTEMIZOLE
CHEMBL296419
|
1988 |
|
|
PERGOLIDE
CHEMBL531
|
1988 |
|
|
PENBUTOLOL
CHEMBL1290
|
1987 |
|
|
OXYMETAZOLINE
CHEMBL762
|
1986 |
|
|
BUSPIRONE HYDROCHLORIDE
CHEMBL1200399
|
1986 |
|
|
BUSPIRONE
CHEMBL49
|
1986 |
|
|
LABETALOL
CHEMBL429
|
1984 |
|
|
OXPRENOLOL
CHEMBL546
|
1983 |
|
|
PINDOLOL
CHEMBL500
|
1982 |
|
|
TRAZODONE
CHEMBL621
|
1981 |
|
|
SULOCTIDIL
CHEMBL404849
|
1979 |
|
|
BROMOCRIPTINE
CHEMBL493
|
1978 |
|
|
TIMOLOL
CHEMBL499
|
1978 |
|
|
DROPERIDOL
CHEMBL1108
|
1970 |
|
|
DOXEPIN
CHEMBL1628227
|
1969 |
|
|
HALOPERIDOL
CHEMBL54
|
1967 |
|
|
PROPRANOLOL
CHEMBL27
|
1967 |
|
|
THIORIDAZINE
CHEMBL479
|
1962 |
|
|
METHYSERGIDE
CHEMBL1065
|
1962 |
|
|
CYPROHEPTADINE
CHEMBL516
|
1961 |
|
|
TRIFLUOPERAZINE
CHEMBL422
|
1959 |
|
|
FLUPHENAZINE
CHEMBL726
|
1959 |
|
|
CHLORPROMAZINE
CHEMBL71
|
1957 |
|
|
PROCHLORPERAZINE
CHEMBL728
|
1956 |
|
|
ERGOTAMINE
CHEMBL442
|
1948 |
|
|
DIHYDROERGOTAMINE
CHEMBL1732
|
1946 |
|
|
METHYLERGONOVINE
CHEMBL1201356
|
1946 |
|
|
MIANSERIN
CHEMBL6437
|
— |
Source Header